Symbols

Karyopharm 2025 Q3 Earnings Revenue Surges 13.6% Despite Widening Net Loss

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team

Tuesday, Nov 4, 2025 5:43 am ET1min read

Aime Summary

- KaryopharmKPTI-- reported 13.6% Q3 revenue growth despite widening net losses, driven by XPOVIO expansion and Phase III SENTRY trial completion.

- CEO Richard Paulson highlighted $100M financing, SENTRY trial progress, and strategic focus on advancing myelofibrosis treatment selinexor plus ruxolitinib.

- Company reaffirmed 2025 revenue guidance ($140-155M) while extending liquidity through clinical advancements and financial discipline measures.

- Mixed earnings results reflect investor skepticism about near-term profitability despite clinical progress and expanded all-oral treatment positioning.

, surpassing expectations, . , . .

Revenue

Product revenue, net, , . .

Earnings/Net Income

, , . Despite a marginal EPS improvement, the broader financial challenges persist, .

Post-Earnings Price Action Review

, . The mixed performance reflects investor skepticism about near-term profitability despite clinical and financial progress.

CEO Commentary

highlighted the completion of the Phase III SENTRY trial for myelofibrosis and $100 million in financing, . He emphasized XPOVIO’s growth and strategic focus on advancing SENTRY, expanding the XPOVIO franchise, and maintaining financial discipline.

Guidance

Karyopharm reaffirmed 2025 total revenue guidance of $140–155 million and U.S. . , .

Additional News

Karyopharm completed enrollment in the Phase III SENTRY trial for myelofibrosis, positioning selinexor plus ruxolitinib as a potential all-oral treatment. , extending liquidity. Additionally, , . , with regulatory and commercial outcomes hinging on these results.

Ainvest Earnings Report Digest

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Karyopharm 2025 Q3 Earnings Revenue Surges 13.6% Despite Widening Net Loss

Latest Articles

Stay ahead of the market.

Comments

AInvestPRO

AInvest

AInvest
PRO